FDA Strives to Harmonize 21 CFR Part 820 with ISO 13485:2016
The Food and Drug Administration (FDA) has continued to move towards harmonizing U.S. regulations with international standards for the regulation of medical devices. On February 23, 2022, FDA published its draft rule, “Medical Devices; Quality System Regulation Amendments,” in the Federal Register. Upon finalization of the new rule, the Quality System Regulation, or QSR, may be renamed the “Quality Management System Regulation,” or QMSR. This new rule strives to harmonize the current Good Manufacturing Practices found in 21 CFR Part 820 Quality System Regulation (QSR) with the international standards found in ISO 13485:2016.
This move by FDA, which will be the first major change to the QSR in over 20 years, will update the prior regulation. However, this effort to harmonize with international standards has been ongoing since 2018 and is in line with FDA’s more recent endeavor to align with international regulatory standards for drugs and devices. Traditionally, medical device manufacturers have relied on 21 CFR Part 820 to ensure compliance with regulatory standards for selling medical devices in the United States while maintaining a separate system for compliance with international standards. They will now be able to ensure compliance with all regulators – both international and domestic – by relying on a single compliance and regulatory standard. There will be some minor differences between the US standard and ISO 13485. Namely, the US standard will speak to records, device labeling, and packaging, because the international standard does not discuss labeling inspection requirements clearly.
By harmonizing these two standards, medical device manufacturers could save hundreds of millions of dollars in the long run[1]. They will also be able to decrease the burden of recordkeeping for two separate sets of regulations by maintaining records that reflect compliance with a single standard for device quality, recordkeeping, and processes. However in the short run, it is estimated that medical device companies are looking at millions of dollars[2] in cost to get in line with the new regulatory standards.
Upon finalization, this rule should go into effect one year from publication in the Federal Register. At that point, it would be prudent for medical device companies to consult with their legal teams to ensure compliance with the new regulations.
[1] https://www.medtechdive.com/news/fda-proposed-rule-quality-requirements-ISO-13485/619244/
[2] Ibid.
How Medmarc Can Help
Life sciences and medical technology companies face complex and evolving risks throughout the product lifecycle. Medmarc provides specialized life sciences insurance, medical device insurance, products liability coverage, and risk management expertise to address the unique exposures of the industry. From emerging technologies and clinical trials to products on the market, Medmarc combines decades of life sciences experience with specialized industry knowledge and insurance solutions.
Explore Medmarc's insurance solutions to learn more about our capabilities, and talk with your insurance broker about your organization’s evolving risks and insurance considerations.
Phone: 888-633-6272
Copyright © 2026 - Medmarc
Related Articles
CMS, FDA Propose New Path for Breakthrough Devices
The Centers for Medicare & Medicaid Services and the FDA recently announced a new program that...Three Years Since the Draft Guidance was Released, FDA Issues their Final Guidance Document on Clinical Decision Support Software
On September 28, 2022, FDA released their 26-page final guidance document titled, “Clinical...Medmarc is a proud member of TDC Specialty. TDC Specialty is the marketing name for the specialty insurance operations and services of The Doctors Company and its subsidiaries and affiliated companies, including TDC Specialty Underwriters, Inc., TDC Specialty Insurance Company, TDC National Assurance Company, Healthcare Risk Advisors, Inc., Hospitals Insurance Company, Inc., ProAssurance Specialty Insurance Company, NORCAL Specialty Insurance Company, and Medmarc Casualty Insurance Company. All products and services are written or provided by subsidiaries or affiliates of The Doctors Company. The Doctors Company does not underwrite excess and surplus lines insurance. Certain coverages may be provided through surplus lines insurance subsidiaries of The Doctors Company through licensed surplus lines brokers. Coverages may be underwritten by TDC Specialty Insurance Company, TDC National Assurance Company, Hospitals Insurance Company, Inc., ProAssurance Specialty Insurance Company, NORCAL Specialty Insurance Company, or Medmarc Casualty Insurance Company. Product summaries are for informational purposes only. Coverage is subject to the language of the policy as actually issued. Coverage, policy terms, and availability may vary by state.
TDC Specialty Underwriters, Inc., is based and domiciled in Connecticut; in California d/b/a Insurance City Solutions (license #0L85833) and in New York, d/b/a TDC Specialty Underwriters Services. Healthcare Risk Advisors, Inc., is based and domiciled in New York.
